About: Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 04 March 2014

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 2014 (uk) article scientifique publié en 2014 (fr) scientific article published on 04 March 2014 (en) artículu científicu espublizáu en marzu de 2014 (ast)
publication date	wds:Q87405997-B259A3BD-E63E-4EE9-961A-498E1AACFAD6
publication date	2014-03-04 00:00:00Z (xsd:dateTime)
author name string	wds:Q87405997-065DA129-926E-462C-B268-F7346DBE8ABB wds:Q87405997-0958EA77-2C51-4CA2-AA3D-FB4104FF2951 wds:Q87405997-144F26C2-03A0-4293-A2B7-28C32856397E wds:Q87405997-35F00930-7FFA-452B-997A-1186138B6E91 wds:Q87405997-3BA366B1-9890-4619-9680-F4CAA4CE282F wds:Q87405997-3C7F0117-39D7-487F-96A7-78729BE9E556 wds:Q87405997-52ECFC79-E247-4F06-8252-FAFEF977500E wds:Q87405997-7276AAFC-5A43-45C1-A8BA-CEB5ADA5CA39 wds:Q87405997-962C62BF-44CF-43CC-BA4A-3E41942C4F58 wds:Q87405997-A9978E80-1C34-4E5C-A412-E972F12FEFC7 wds:Q87405997-BABF9471-EE76-463E-A85B-7FEBB4B08F82 wds:Q87405997-BAF73E9F-109E-4B55-99CD-513303072DEF wds:Q87405997-CF4F0341-4547-45C5-9F39-1FEE666261C8 wds:Q87405997-EAD5E66A-1A28-47BD-AD37-F1301A9FE8BD
author name string	Robert Weiss Scott M Wasserman Marc S Sabatine Jingyuan Yang Evan A Stein Frederick J Raal David Sullivan Jae B Kim Michael J Koren Thomas Liu Moetaz Albizem Ransi Somaratne Eli M Roth PROFICIO Investigators
rdfs:label	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials (en) Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials (nl)
skos:prefLabel	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials (en) Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials (nl)
name	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials (en) Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials (nl)
author	wds:Q87405997-258836D0-BFBE-405F-A444-B6255D1C6B4C wds:Q87405997-DC54BA26-93E3-4C05-A77A-7421613CFEFF
author	Robert P Giugliano Robert Scott
title	wds:Q87405997-EEC1EAC5-3755-446C-8927-AABA4F214599
title	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials (en)
page(s)	wds:Q87405997-2CEA873F-B80E-4EEF-B123-21D8F3D1D9BA
page(s)	2249-2259
instance of	wds:Q87405997-2f904792-1468-4457-b1e0-5bf69e422b28 wds:Q87405997-F431B780-240F-46F5-8FD9-508CA0C34C8D
instance of	meta-analysis scholarly article
main subject	wds:Q87405997-02F9AFD9-4369-45CA-9F84-F28E281C204B wds:Q87405997-CE6D2420-420D-4012-9B88-66DFFC04AF12
main subject	monoclonal antibody phase II clinical trial
PubMed ID	wds:Q87405997-53644ED1-E3A6-4425-B9AC-05ABB730D78E
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24598985
PubMed ID	24598985
published in	wds:Q87405997-35B904F1-3D2B-4A4B-829D-27F4053603EC
published in	European Heart Journal
issue	wds:Q87405997-740AC169-C80E-4B2B-B006-B085456FFEBF
volume	wds:Q87405997-6A26CA1B-F0BF-40CB-AB13-8E36604DD6DE
issue	33
volume	35
DOI	wds:Q87405997-028F71FE-F955-4BFA-9576-766B527E0BD7
DOI	http://dx.doi.org/10.1093/EURHEARTJ/EHU085
DOI	10.1093/EURHEARTJ/EHU085
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q87405997
is cites work of	Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study Shared genetic aetiology of coronary artery disease and atherosclerotic stroke - 2015. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies New Era of Lipid-Lowering Drugs PCSK9 and triglyceride-rich lipoprotein metabolism Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials Management of Statin Intolerance in 2018: Still More Questions Than Answers. PCSK9 inhibition: current concepts and lessons from human genetics Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. The role of lipoprotein (a) in chronic kidney disease. PCSK9 inhibition: the dawn of a new age in cholesterol lowering? Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. Acute and chronic impact of cardiovascular events on health state utilities Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting PCSK9 antibodies for the treatment of hypercholesterolemia Retargeting the management of hypercholesterolemia - focus on evolocumab Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease The 1st and the 2nd Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software